| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,400 | 5,650 | 30.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 22,200 | 30 | |||
| 19,600 | 2 | |||
| 16,000 | 500 | |||
| 15,000 | 15 | |||
| 5,650 | 656 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 656 | 5,400 | |||
| 450 | 5,300 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.167 | 0,555 | 1.203 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 12:04:52 | 5,900 | 500 |
| Tagesumsatz Xetra | -0,300 -5,04 % | 2.120 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | IN BRIEF: 4basebio appoints Scott Lorimer as chief operating officer | 5 | Alliance News | ||
| 12.03. | 4basebio Plc - Appointment of COO | 345 | PR Newswire | 4basebio Plc - Appointment of COO
PR Newswire
LONDON, United Kingdom, March 12
THIS... ► Artikel lesen | |
| 09.03. | 4basebio promotes Christine Wolosin to chief commercial officer | 14 | Alliance News | ||
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 03.03. | 4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer | 240 | GlobeNewswire (Europe) | Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP, Marketing... ► Artikel lesen | |
| 03.03. | 4basebio Plc - Appointment of CCO | 270 | PR Newswire | 4basebio Plc - Appointment of CCO
PR Newswire
LONDON, United Kingdom, March 03
THIS... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mo | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| Mo | Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results | ACCESS Newswire | ~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)... ► Artikel lesen | |
| Mo | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erteilt Taisho Pharmaceutical eine Lizenz für seine RenNano-Plattform zur Entwicklung von vollständig humanen, ausschließlich aus schweren Ketten bestehenden Antikörpern | Business Wire | Biocytogen Pharmaceuticals (Peking) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das die Forschung und Entwicklung neuartiger, auf Antikörpern... ► Artikel lesen | |
| Mo | Immix Biopharma, Inc.: Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones | GlobeNewswire (Europe) | - Full enrollment of BLA-enabling trial complete, per prior guidance -- Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch -- Onboarded Chief Medical... ► Artikel lesen | |
| Mo | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen |